EUVIMEDEUVIMED entdecken
Crossref

Development of engineered transferosomal gel containing meloxicam for the treatment of osteoarthritis

Rahul Maheshwari, Mayank Sharma, Vijay R Chidrawar

Annales Pharmaceutiques Françaises · 2024

DOI: 10.1016/j.pharma.2024.04.006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Annales Pharmaceutiques Françaises, 2024. Verfasst von Rahul Maheshwari und 2 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS) Deemed-to-University, Green Industrial Par…. Hauptthemen laut MEDLINE: Meloxicam, Gels, Osteoarthritis, Thiazoles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 55 Literaturangaben. Gefördert von: Department of Science and Technology, Ministry of Science and Technology, India, Science and Engineering Research Board.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: .In this study, we investigated the potential of meloxicam (MLX) developed as transferosomal gel as a novel lipidic drug delivery system to address osteoarthritis (OTA), a degenerative joint disease that causes pain and stiffness. By incorporating meloxicam into a transferosomal gel, our aim was to provide a targeted and efficient delivery system capable of alleviating symptoms and slowing down the progression of OTA. MATERIAL AND METHODS: Classical lipid film hydration technique was utilized to formulate different transferosomal formulations. Different transferosomal formulations were prepared by varying the molar ratio of phospholipon-90H (phosphodylcholine) to DSPE (50:50, 60:40, 70:30, 80:20, and 90:10) and per batch, 80mg of total lipid was used. The quality control parameters such as entrapment efficiency, particle size and morphology, polydispersity and surface electric charge, in vitro drug release, ex vivo permeation and stability were measured. RESULTS: The optimized transferosomal formulations revealed a small vesicle size (121±12nm) and greater MLX entrapment (68.98±2.3%). Transferosomes mediated gel formulation MLX34 displayed pH (6.3±0.2), viscosity (6236±12.3 cps), spreadability (13.77±1.77 gm.cm/sec) and also displayed sustained release pattern of drug release (81.76±7.87% MLX released from Carbopol-934 gel matrix in 24h). MLX34 revealed close to substantial anti-inflammatory response, with ∼81% inhibition of TNF-α in 48h. Physical stability analysis concluded that refrigerator temperature was the preferred temperature to store transferosomal gel. CONCLUSION: MLX loaded transferosomes containing gel improved the skin penetration and therefore resulted into increased inhibition of TNF-α level.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MeloxicamGelsOsteoarthritisThiazolesThiazinesLiposomesAnti-Inflammatory Agents, Non-SteroidalDrug LiberationAnimalsParticle SizeDrug Delivery SystemsDrug StabilitySkin AbsorptionChemistry, Pharmaceutical

Stichwörter der Autor:innen

Administration de médicaments à base de lipidesArthroseCinétique in vitroIn vitro kineticsLipid based drug deliveryMeloxicamMéloxicamOsteoarthritisPerméation cutanéeSkin permeationTransferosomesTransférosomes

Substanzen

MeloxicamGelsThiazolesThiazinesLiposomesAnti-Inflammatory Agents, Non-Steroidal

Autor:innen und Institutionen

  • School of Pharmacy and Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS) Deemed-to-University, Green Industrial Park, TSIIC, Jadcherla, Hyderabad 509301, India. Electronic address: rahu…
  • School of Pharmacy and Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS) Deemed-to-University, Shirpur 425405, India.
  • School of Pharmacy and Technology Management, SVKM's Narsee Monjee Institute of Management Studies (NMIMS) Deemed-to-University, Green Industrial Park, TSIIC, Jadcherla, Hyderabad 509301, India.

Förderung

  • Department of Science and Technology, Ministry of Science and Technology, India
  • Science and Engineering Research Board

Zitieren

APA

Maheshwari, R., Sharma, M., & Chidrawar, V. R. (2024). Development of engineered transferosomal gel containing meloxicam for the treatment of osteoarthritis. Annales Pharmaceutiques Françaises. https://doi.org/10.1016/j.pharma.2024.04.006

Vancouver

Maheshwari R, Sharma M, Chidrawar VR. Development of engineered transferosomal gel containing meloxicam for the treatment of osteoarthritis. Annales Pharmaceutiques Françaises. 2024. doi:10.1016/j.pharma.2024.04.006

BibTeX
@article{Maheshwari2024,
  author = {Maheshwari, Rahul and Sharma, Mayank and Chidrawar, Vijay R},
  title = {Development of engineered transferosomal gel containing meloxicam for the treatment of osteoarthritis},
  journal = {Annales Pharmaceutiques Françaises},
  year = {2024},
  doi = {10.1016/j.pharma.2024.04.006}
}
Kostenlos starten →